Literature DB >> 26891154

Trading scalpels for sheaths: Catheter-based treatment of vascular injury can be effectively performed by acute care surgeons trained in endovascular techniques.

Megan Brenner1, Melanie Hoehn, William Teeter, Deborah Stein, Thomas Scalea.   

Abstract

BACKGROUND: The skill set of the acute care surgeon can be expanded by formal training. We report the first series of traumatic vascular injury (TVI) treated by acute care surgeons trained in endovascular techniques (ACSTEV).
METHODS: We retrospectively reviewed patients admitted to our trauma center with TVI over 5 months who survived for more than 24 hours and had catheter diagnosis and/or therapy by ACSTEV. Demographics, admission data, and outcomes were reviewed. Follow-up ranged from 0 day to 150 days.
RESULTS: Most patients were male (63%) and sustained blunt mechanism (91%). Mean (SD) age was 48.2 (21.9) years, and mean (SD) Injury Severity Score was 32.1 (11.8). Mean (SD) admission systolic blood pressure, heart rate, Glasgow Coma Scale (GCS) score were 126.12 (30.4) mm Hg, 101.21 (28.2) beats per minute, and 10.8 (4.73), respectively. Forty-six patients underwent 48 endovascular procedures for TVI: 32 angiograms and 16 venograms were obtained. Two pelvic angiograms and one aortic arch angiogram were negative and required no treatment. One superficial femoral artery arteriogram showed minor luminal defects requiring anticoagulation only. Pseudoaneurysms were found in 17 vessels, vessel truncation in 4, active extravasation in 5, stenosis in 1, and dissection with thrombus in 1. Four patients had resuscitative endovascular balloon occlusion of the aorta performed before catheter intervention for pelvic hemorrhage. Procedures included aortic repair (4), pelvic embolization (13), splenic embolization (5), lumbar artery embolization (1), bronchial artery embolization (1), profunda artery embolization (1), common carotid artery stent (1), celiac artery stent (1), inferior vena cava filter placement (14) and retrieval (2), and pharmacomechanical thrombolysis (1). Treatment material included coils (12), Gelfoam (4), and nitinol plugs (3). No procedural or device-related complications occurred. Mortality was 14.7% unrelated to any endovascular procedure. One patient had repeat coil embolization of a pelvic pseudoaneurysm on postoperative Day 7.
CONCLUSION: ACSTEV can safely treat TVI with good success. We performed nearly 10 procedures per month underscoring the role of the ACSTEV for training and care of TVI in a high-volume trauma center. LEVEL OF EVIDENCE: Therapeutic study, level V.

Entities:  

Mesh:

Year:  2016        PMID: 26891154     DOI: 10.1097/TA.0000000000001006

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  4 in total

1.  Impact of a streamlined trauma management approach and determinants of mortality among hemodynamically unstable patients with severe multiple injuries: a before-and-after retrospective cohort study.

Authors:  Hiroyuki Otsuka; Atsushi Uehata; Naoki Sakoda; Toshiki Sato; Keiji Sakurai; Hiromichi Aoki; Takeshi Yamagiwa; Shinichi Iizuka; Sadaki Inokuchi
Journal:  Trauma Surg Acute Care Open       Date:  2020-09-25

Review 2.  Evidence-Based Management and Controversies in Blunt Splenic Trauma.

Authors:  D C Olthof; C H van der Vlies; J C Goslings
Journal:  Curr Trauma Rep       Date:  2017-02-09

3.  Partial resuscitative balloon occlusion of the aorta (P-REBOA): Clinical technique and rationale.

Authors:  M Austin Johnson; Lucas P Neff; Timothy K Williams; Joseph J DuBose
Journal:  J Trauma Acute Care Surg       Date:  2016-11       Impact factor: 3.313

4.  Availability of on-site acute vascular interventional radiology techniques performed by trained acute care specialists: A single-emergency center experience.

Authors:  Junya Tsurukiri; Shoichi Ohta; Shiro Mishima; Hiroshi Homma; Eitaro Okumura; Itsuro Akamine; Masahito Ueno; Jun Oda; Tetsuo Yukioka
Journal:  J Trauma Acute Care Surg       Date:  2017-01       Impact factor: 3.313

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.